David Schenkein Net Worth

The estimated Net Worth of David P Schenkein is at least $30.1 Milion dollars as of 13 June 2024. David Schenkein owns over 3,388 units of Agios Pharmaceuticals Inc stock worth over $5,593,783 and over the last 11 years he sold AGIO stock worth over $21,902,874. In addition, he makes $2,576,380 as Executive Chairman of the Board at Agios Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Schenkein AGIO stock SEC Form 4 insiders trading

David has made over 80 trades of the Agios Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 3,388 units of AGIO stock worth $150,122 on 13 June 2024.

The largest trade he's ever made was exercising 80,000 units of Agios Pharmaceuticals Inc stock on 4 October 2017 worth over $24,000. On average, David trades about 11,641 units every 33 days since 2014. As of 13 June 2024 he still owns at least 126,242 units of Agios Pharmaceuticals Inc stock.

You can see the complete history of David Schenkein stock trades at the bottom of the page.

David Schenkein biography

Dr. David P. Schenkein M.D. serves as Executive Chairman of the Board of the Company. Dr. Schenkein has served as a member of our board of directors since August 2009 and as our executive chairman since February 2019. Dr. Schenkein also served as our president and chief executive officer from August 20019 until February 2019. Dr. Schenkein has been a hematologist and medical oncologist for more than 20 years. He currently serves as a general partner of GV, the venture capital arm of Alphabet Inc. (formerly Google), and is an adjunct attending physician in hematology at Tufts Medical Center. Prior to joining Agios, from 2006 to 2009, Dr. Schenkein was the senior vice president, clinical hematology/oncology at Genentech, Inc., a pharmaceutical company (now a member of the Roche Group, a global healthcare company), or Genentech, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for its bio-oncology portfolio. While at Genentech, he served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the senior vice president of clinical research at Millennium Pharamaceutials, Inc., a biopharmaceutical company (now Takeda Oncology), or Millennium, overseeing the clinical development and worldwide approval of VELCADE®, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. Dr. Schenkein currently serves on the board of directors of bluebird bio, Inc. and Denali Therapeutics Inc., both public biotechnology companies, and was formerly on the board of Foundation Medicine, Inc., a public biotechnology company. Dr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.

What is the salary of David Schenkein?

As the Executive Chairman of the Board of Agios Pharmaceuticals Inc, the total compensation of David Schenkein at Agios Pharmaceuticals Inc is $2,576,380. There are 3 executives at Agios Pharmaceuticals Inc getting paid more, with Jacqualyn Fouse having the highest compensation of $16,608,000.

How old is David Schenkein?

David Schenkein is 62, he's been the Executive Chairman of the Board of Agios Pharmaceuticals Inc since 2019. There are 8 older and 15 younger executives at Agios Pharmaceuticals Inc. The oldest executive at Agios Pharmaceuticals Inc is Dr. Tak Wah Mak, 75, who is the Co-Founder & Member of Scientific Advisory Board.

Insiders trading at Agios Pharmaceuticals Inc

Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over $77,887,085 worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth $154,554,190 . The most active insiders traders include Kevin P Starr, Robert Nelsen a John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $765,588. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth $102,002.

What does Agios Pharmaceuticals Inc do?

at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible

Complete history of David Schenkein stock trades at Agios Pharmaceuticals Inc, Bluebird bio Inc, Regeneron Pharmaceuticals a Denali Therapeutics Inc

Agios Pharmaceuticals Inc executives and stock owners

Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jacqualyn Fouse,
  Chief Executive Officer, Director
• Christopher Bowden,
  Chief Medical Officer
• Jonathan Biller,
  Chief Financial Officer, Head of Legal and Corporate Affairs
• David Schenkein,
  Executive Chairman of the Board
• Dr. Sarah Gheuens M.D., Ph.D.,
  Chief Medical Officer
• Dr. Jacqualyn A. Fouse,
  CEO & Director
• Dr. Bruce Car Ph.D.,
  Chief Scientific Officer
• Jonathan Biller J.D.,
  CFO & Head of Corp. Affairs
• Richa Poddar,
  Chief Commercial Officer
• John Maraganore,
  Independent Director
• Kaye Foster,
  Independent Director
• Paul Clancy,
  Independent Director
• Maykin Ho,
  Independent Director
• David Scadden,
  Director
• Ian Clark,
  Independent Director
• Holly Manning,
  IR Contact Officer
• Bruce Car,
  Chief Scientific Officer
• Dr. Craig B. Thompson M.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Kendra Adams,
  VP of External Communications & Investor Relations
• Dr. Clive Patience Ph.D.,
  Chief Technical Operations Officer
• T. J. Washburn Jr.,
  Principal Accounting Officer
• Dr. Shin-San Su Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Dr. Craig B. Thompson,
  Co-Founder & Chairman of Scientific Advisory Board
• Dr. Tak Wah Mak,
  Co-Founder & Member of Scientific Advisory Board
• Dr. Lewis Clayton Cantley Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Lewis Clayton Jr. Cantley,
  Director
• Carman Alenson,
  Principal Accounting Officer
• Scott Biller,
  Chief Scientific Officer
• Douglas G. Cole,
  Director
• Steven L. Hoerter,
  Chief Commercial Officer
• Marc Tessier Lavigne,
  Director
• Robert Nelsen,
  Director
• European Investment Co Llc ...,
  
• Corp /De/Celgene Switzerlan...,
  
• Sarah Gheuens,
  Chief Medical Officer
• Ventures Fund 2007, L.P.Afe...,
  
• Venture Fund Vii Lparch Ven...,
  
• European Investment Co Llc ...,
  10% owner
• European Investment Co Llcc...,
  
• Rock Ventures Lp Third Rock...,
  
• Kevin P Starr,
  Director
• Glenn Goddard,
  Senior Vice President, Finance
• John Duncan Higgons,
  Chief Operating Officer
• Venture Fund Vii Lparch Ven...,
  
• Perry A Karsen,
  Director
• Corp /De/Celgene European I...,
  
• Catherine E. Owen,
  Director
• Cecilia Jones,
  Chief Financial Officer
• Theodore James Jr. Washburn,
  Principal Accounting Officer
• Darrin Miles,
  Chief Commercial Officer
• Richa Poddar,
  Chief Commercial Officer
• James William Burns,
  Chief Legal Officer
• Brian Goff,
  Chief Executive Officer
• Rahul D. Ballal,
  Director
• Cynthia Smith,
  Director
• Tsveta Milanova,
  Chief Commercial Officer
• Jeffrey D Capello,
  Director